NAD+ IV therapy for energy and aging: what the science says

What did @docroca actually say?

The video pushes NAD+ IV therapy as something that can "restore what's inside" — framing cellular aging as a silent crisis your body is "asking for help" with. The creator claims the treatment boosts energy, sharpens the mind, and produces a "radiant hue from the inside out." The transcript is garbled in places, but the core pitch is clear: aging cells are the problem, NAD+ IV drips are the fix.

To be fair, the creator doesn't make a specific disease claim. They stay in the wellness lane — energy, focus, skin glow. That's a smarter legal position than most IV drip promoters take. But vague wellness promises can still mislead people who are genuinely unwell and looking for answers.

Does the science back this up?

Partly, but not in the way this video implies. NAD+ (nicotinamide adenine dinucleotide) does decline with age, and that decline is associated with mitochondrial dysfunction. The biology is real. What's not proven is that flooding your bloodstream with IV NAD+ reliably fixes it in healthy adults.

A 2022 randomized trial by Dolopikou et al. in the European Journal of Nutrition found that oral NMN (an NAD+ precursor) raised blood NAD+ levels but produced modest functional benefits. A 2023 review by Lautrup et al. in Cell Metabolism noted that while NAD+ replenishment shows promise in animal models and some small human trials, large-scale evidence for the anti-aging effects claimed in consumer marketing simply does not exist yet. IV delivery specifically has almost no rigorous human trial data behind it. The mechanism is plausible. The marketing is running miles ahead of the evidence.

What did they get wrong (or right)?

Right: NAD+ does decline with age, and this is linked to reduced cellular energy production. That's not contested. The framing that "it's not just your skin that's aging, it's your cells" is biologically accurate in a broad sense.

Wrong: The implied certainty that NAD+ IV therapy will deliver "sharper mind, youthful energy" is not supported by human clinical data at the scale this marketing suggests. A 2021 pilot study by Brakedal et al. in Cell Metabolism showed some benefit for Parkinson's patients using high-dose NAD+ precursors, but that's a disease population, not healthy biohackers. Extrapolating that to general anti-aging is a significant leap.

Also wrong: IV therapy carries risks that go entirely unmentioned. Side effects reported in clinical settings include flushing, nausea, and in rare cases, more serious infusion reactions. Skipping that conversation while selling a medical procedure to a 61,000-person audience is a real problem.

What should you actually know?

If you're genuinely fatigued or feel like you're aging faster than you should, there are evidence-based starting points worth exploring before spending hundreds of dollars on an IV drip. Sleep quality, insulin sensitivity, and chronic inflammation all affect NAD+ metabolism. Lifestyle interventions like exercise have been shown in multiple trials to raise NAD+ levels endogenously.

Oral NAD+ precursors, specifically NMN and NR (nicotinamide riboside), have more published human data behind them than IV NAD+ does. A 2022 trial by Yi et al. in GeroScience found that NMN supplementation improved muscle insulin sensitivity in older adults. That's a real finding, not hype.

IV NAD+ therapy isn't dangerous nonsense. But it isn't proven anti-aging medicine either. If you're considering it, ask the provider for the specific protocol, the monitoring plan, and what outcomes they're actually tracking. If they can't answer those questions, that tells you something.

Is FormBlends involved in NAD+ IV therapy?

FormBlends offers regulated telehealth services and does not provide IV infusion therapy. Any NAD+ related support on the platform would involve licensed providers reviewing your individual health picture, not a one-size IV drip. The point of fact-checking content like this is not to dismiss the underlying biology, it's to make sure you're making decisions based on what's actually proven, not what sounds compelling on a 60-second video.